Glaukos (GKOS) Q2 FY26 earnings call

Glaukos delivered a record second quarter, driven by strong performance across its U.S. glaucoma and Corneal Health franchises, particularly from the successful launches of iDose TR and Epioxa. The company raised its full-year net sales guidance, reflecting confidence in its diversified technology platforms and pipeline advancements. Management remains focused on strategic investments in commercial infrastructure and R&D while aiming for sustained operating leverage and cash flow generation.